CN1798845A - 黄病毒复制子包装系统 - Google Patents

黄病毒复制子包装系统 Download PDF

Info

Publication number
CN1798845A
CN1798845A CNA200480015488XA CN200480015488A CN1798845A CN 1798845 A CN1798845 A CN 1798845A CN A200480015488X A CNA200480015488X A CN A200480015488XA CN 200480015488 A CN200480015488 A CN 200480015488A CN 1798845 A CN1798845 A CN 1798845A
Authority
CN
China
Prior art keywords
packaging
flavivirus
replicon
cells
kun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480015488XA
Other languages
English (en)
Chinese (zh)
Inventor
亚历山大·A.·赫罗梅赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIO TECH Co Ltd
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of CN1798845A publication Critical patent/CN1798845A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA200480015488XA 2003-06-06 2004-06-07 黄病毒复制子包装系统 Pending CN1798845A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003902842A AU2003902842A0 (en) 2003-06-06 2003-06-06 Flavivirus replicon packaging system
AU2003902842 2003-06-06

Publications (1)

Publication Number Publication Date
CN1798845A true CN1798845A (zh) 2006-07-05

Family

ID=31953883

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480015488XA Pending CN1798845A (zh) 2003-06-06 2004-06-07 黄病毒复制子包装系统

Country Status (8)

Country Link
US (1) US20060280757A1 (https=)
EP (1) EP1633877A4 (https=)
JP (1) JP2006526393A (https=)
CN (1) CN1798845A (https=)
AU (1) AU2003902842A0 (https=)
CA (1) CA2528046A1 (https=)
NZ (1) NZ543419A (https=)
WO (1) WO2004108936A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102363751A (zh) * 2011-03-24 2012-02-29 中山大学 登革病毒样颗粒及其制备方法与应用
CN111343998A (zh) * 2017-09-11 2020-06-26 天甲生物医药有限公司 哺乳动物特异性的生长缺陷的虫媒病毒
CN113637697A (zh) * 2021-07-13 2021-11-12 中山大学 一种denv-4全长感染性克隆及其构建方法
WO2023109975A3 (zh) * 2021-12-17 2023-08-10 华南理工大学 提高基因表达的rna复制子及其应用
CN119899808A (zh) * 2024-12-05 2025-04-29 深圳湾实验室 登革减毒株及其应用
CN120818539A (zh) * 2025-09-16 2025-10-21 成都锦城学院 黄病毒的复制依赖的rna重组实验系统的建立和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986686A4 (en) * 2006-02-13 2010-08-11 Integral Molecular Inc DENGUE REPORTERVIRUS AND METHOD FOR ITS MANUFACTURE AND USE
KR101499750B1 (ko) 2006-02-27 2015-03-06 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 가감염성 플라비바이러스 및 이들의 용도
JP5779352B2 (ja) 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
ES2544702T3 (es) * 2008-07-17 2015-09-02 Medigen, Inc. Vacunas en forma de ADNi y métodos para utilizarlas
EP3105311A1 (en) 2014-02-10 2016-12-21 Univercells NV System, apparatus and method for biomolecules production
PL3294893T3 (pl) * 2015-05-13 2024-04-29 Csl Behring Gene Therapy, Inc. Bioprodukcja wektorów lentiwirusowych
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893866B1 (en) * 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
NZ533237A (en) * 2001-11-26 2005-11-25 Univ Queensland Flavivirus vaccine delivery system
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102363751A (zh) * 2011-03-24 2012-02-29 中山大学 登革病毒样颗粒及其制备方法与应用
CN111343998A (zh) * 2017-09-11 2020-06-26 天甲生物医药有限公司 哺乳动物特异性的生长缺陷的虫媒病毒
CN113637697A (zh) * 2021-07-13 2021-11-12 中山大学 一种denv-4全长感染性克隆及其构建方法
WO2023109975A3 (zh) * 2021-12-17 2023-08-10 华南理工大学 提高基因表达的rna复制子及其应用
CN119899808A (zh) * 2024-12-05 2025-04-29 深圳湾实验室 登革减毒株及其应用
CN120818539A (zh) * 2025-09-16 2025-10-21 成都锦城学院 黄病毒的复制依赖的rna重组实验系统的建立和应用

Also Published As

Publication number Publication date
EP1633877A1 (en) 2006-03-15
JP2006526393A (ja) 2006-11-24
WO2004108936A1 (en) 2004-12-16
CA2528046A1 (en) 2004-12-16
AU2003902842A0 (en) 2003-06-26
NZ543419A (en) 2008-04-30
EP1633877A4 (en) 2007-08-22
US20060280757A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
EP2916864B1 (en) Compositions, methods and uses for dengue virus serotype-4 constructs
EP2989205B1 (en) Bacterial artificial chromosomes
CN1791678A (zh) 改进的甲病毒复制子和辅助构建体
JP2020534256A (ja) 免疫原性チクングニアウイルスｃｈｉｋｖ−ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法
JP2009528032A (ja) 偽感染性フラビウイルスおよびそれらの使用
CN1798845A (zh) 黄病毒复制子包装系统
CN1688702A (zh) 表达rna病毒抗原表位的重组麻疹病毒在制备疫苗组合物中的用途
US20250057932A1 (en) Vaccines against infectious diseases caused by positive stranded rna viruses
JP5816614B2 (ja) 感染性ｃ型肝炎ウイルス高生産ｈｃｖ変異体及びその利用
CN1671851A (zh) 黄病毒疫苗输送系统
Nickols et al. Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice
EP2999781B1 (en) Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses
AU2009211379B2 (en) Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
HK1094003A (en) Flavivirus replicon packaging system
CN1489630A (zh) Hiv样颗粒及其用途
AU2004245578B2 (en) Flavivirus replicon packaging system
US11351240B2 (en) Chimeric yellow fever ZIKA virus strain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1094003

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: LEIPRIQUEEN BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: UNIV QUEENSLAND

Effective date: 20080725

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080725

Address after: Queensland, Australia

Applicant after: Bio Tech Co., Ltd.

Address before: Queensland, Australia

Applicant before: University of Queensland

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060705

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1094003

Country of ref document: HK